Report Detail

Request for Sample of this report

Other Global Biopharmaceutical CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM4562433
    • |
  • 21 October, 2023
    • |
  • Global
    • |
  • 110 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Other

According to our (Global Info Research) latest study, the global Biopharmaceutical CDMO market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
The Global Info Research report includes an overview of the development of the Biopharmaceutical CDMO industry chain, the market status of Pharmaceutical Company (Development and Manufacturing CDMOs, Clinical Trial Material CDMOs), Biotechnology Company (Development and Manufacturing CDMOs, Clinical Trial Material CDMOs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Biopharmaceutical CDMO.
Regionally, the report analyzes the Biopharmaceutical CDMO markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Biopharmaceutical CDMO market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Biopharmaceutical CDMO market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Biopharmaceutical CDMO industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Development and Manufacturing CDMOs, Clinical Trial Material CDMOs).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Biopharmaceutical CDMO market.
Regional Analysis: The report involves examining the Biopharmaceutical CDMO market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Biopharmaceutical CDMO market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Biopharmaceutical CDMO:
Company Analysis: Report covers individual Biopharmaceutical CDMO players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Biopharmaceutical CDMO This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Pharmaceutical Company, Biotechnology Company).
Technology Analysis: Report covers specific technologies relevant to Biopharmaceutical CDMO. It assesses the current state, advancements, and potential future developments in Biopharmaceutical CDMO areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Biopharmaceutical CDMO market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Biopharmaceutical CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Development and Manufacturing CDMOs
Clinical Trial Material CDMOs
Fill-Finish CDMOs
Other
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Market segment by players, this report covers
Lonza
WuXi AppTec
Catalent
Thermo Fisher
Recipharm
Samsung Biologics
Siegfried
Delpharm
Boehringer Ingelheim
Aenova Group
AGC Parma Chemicals
GenScript
ProBioGen
KBI Biopharma
3P Biopharmaceuticals
Rentschler Biopharma
Northway Biotech
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biopharmaceutical CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biopharmaceutical CDMO, with revenue, gross margin and global market share of Biopharmaceutical CDMO from 2018 to 2023.
Chapter 3, the Biopharmaceutical CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Biopharmaceutical CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biopharmaceutical CDMO.
Chapter 13, to describe Biopharmaceutical CDMO research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Biopharmaceutical CDMO
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Biopharmaceutical CDMO by Type
    • 1.3.1 Overview: Global Biopharmaceutical CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Biopharmaceutical CDMO Consumption Value Market Share by Type in 2022
    • 1.3.3 Development and Manufacturing CDMOs
    • 1.3.4 Clinical Trial Material CDMOs
    • 1.3.5 Fill-Finish CDMOs
    • 1.3.6 Other
  • 1.4 Global Biopharmaceutical CDMO Market by Application
    • 1.4.1 Overview: Global Biopharmaceutical CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Pharmaceutical Company
    • 1.4.3 Biotechnology Company
    • 1.4.4 Other
  • 1.5 Global Biopharmaceutical CDMO Market Size & Forecast
  • 1.6 Global Biopharmaceutical CDMO Market Size and Forecast by Region
    • 1.6.1 Global Biopharmaceutical CDMO Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Biopharmaceutical CDMO Market Size by Region, (2018-2029)
    • 1.6.3 North America Biopharmaceutical CDMO Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Biopharmaceutical CDMO Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Biopharmaceutical CDMO Market Size and Prospect (2018-2029)
    • 1.6.6 South America Biopharmaceutical CDMO Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Biopharmaceutical CDMO Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Lonza
    • 2.1.1 Lonza Details
    • 2.1.2 Lonza Major Business
    • 2.1.3 Lonza Biopharmaceutical CDMO Product and Solutions
    • 2.1.4 Lonza Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Lonza Recent Developments and Future Plans
  • 2.2 WuXi AppTec
    • 2.2.1 WuXi AppTec Details
    • 2.2.2 WuXi AppTec Major Business
    • 2.2.3 WuXi AppTec Biopharmaceutical CDMO Product and Solutions
    • 2.2.4 WuXi AppTec Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 WuXi AppTec Recent Developments and Future Plans
  • 2.3 Catalent
    • 2.3.1 Catalent Details
    • 2.3.2 Catalent Major Business
    • 2.3.3 Catalent Biopharmaceutical CDMO Product and Solutions
    • 2.3.4 Catalent Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Catalent Recent Developments and Future Plans
  • 2.4 Thermo Fisher
    • 2.4.1 Thermo Fisher Details
    • 2.4.2 Thermo Fisher Major Business
    • 2.4.3 Thermo Fisher Biopharmaceutical CDMO Product and Solutions
    • 2.4.4 Thermo Fisher Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Thermo Fisher Recent Developments and Future Plans
  • 2.5 Recipharm
    • 2.5.1 Recipharm Details
    • 2.5.2 Recipharm Major Business
    • 2.5.3 Recipharm Biopharmaceutical CDMO Product and Solutions
    • 2.5.4 Recipharm Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Recipharm Recent Developments and Future Plans
  • 2.6 Samsung Biologics
    • 2.6.1 Samsung Biologics Details
    • 2.6.2 Samsung Biologics Major Business
    • 2.6.3 Samsung Biologics Biopharmaceutical CDMO Product and Solutions
    • 2.6.4 Samsung Biologics Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Samsung Biologics Recent Developments and Future Plans
  • 2.7 Siegfried
    • 2.7.1 Siegfried Details
    • 2.7.2 Siegfried Major Business
    • 2.7.3 Siegfried Biopharmaceutical CDMO Product and Solutions
    • 2.7.4 Siegfried Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Siegfried Recent Developments and Future Plans
  • 2.8 Delpharm
    • 2.8.1 Delpharm Details
    • 2.8.2 Delpharm Major Business
    • 2.8.3 Delpharm Biopharmaceutical CDMO Product and Solutions
    • 2.8.4 Delpharm Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Delpharm Recent Developments and Future Plans
  • 2.9 Boehringer Ingelheim
    • 2.9.1 Boehringer Ingelheim Details
    • 2.9.2 Boehringer Ingelheim Major Business
    • 2.9.3 Boehringer Ingelheim Biopharmaceutical CDMO Product and Solutions
    • 2.9.4 Boehringer Ingelheim Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Boehringer Ingelheim Recent Developments and Future Plans
  • 2.10 Aenova Group
    • 2.10.1 Aenova Group Details
    • 2.10.2 Aenova Group Major Business
    • 2.10.3 Aenova Group Biopharmaceutical CDMO Product and Solutions
    • 2.10.4 Aenova Group Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Aenova Group Recent Developments and Future Plans
  • 2.11 AGC Parma Chemicals
    • 2.11.1 AGC Parma Chemicals Details
    • 2.11.2 AGC Parma Chemicals Major Business
    • 2.11.3 AGC Parma Chemicals Biopharmaceutical CDMO Product and Solutions
    • 2.11.4 AGC Parma Chemicals Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 AGC Parma Chemicals Recent Developments and Future Plans
  • 2.12 GenScript
    • 2.12.1 GenScript Details
    • 2.12.2 GenScript Major Business
    • 2.12.3 GenScript Biopharmaceutical CDMO Product and Solutions
    • 2.12.4 GenScript Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 GenScript Recent Developments and Future Plans
  • 2.13 ProBioGen
    • 2.13.1 ProBioGen Details
    • 2.13.2 ProBioGen Major Business
    • 2.13.3 ProBioGen Biopharmaceutical CDMO Product and Solutions
    • 2.13.4 ProBioGen Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 ProBioGen Recent Developments and Future Plans
  • 2.14 KBI Biopharma
    • 2.14.1 KBI Biopharma Details
    • 2.14.2 KBI Biopharma Major Business
    • 2.14.3 KBI Biopharma Biopharmaceutical CDMO Product and Solutions
    • 2.14.4 KBI Biopharma Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 KBI Biopharma Recent Developments and Future Plans
  • 2.15 3P Biopharmaceuticals
    • 2.15.1 3P Biopharmaceuticals Details
    • 2.15.2 3P Biopharmaceuticals Major Business
    • 2.15.3 3P Biopharmaceuticals Biopharmaceutical CDMO Product and Solutions
    • 2.15.4 3P Biopharmaceuticals Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 3P Biopharmaceuticals Recent Developments and Future Plans
  • 2.16 Rentschler Biopharma
    • 2.16.1 Rentschler Biopharma Details
    • 2.16.2 Rentschler Biopharma Major Business
    • 2.16.3 Rentschler Biopharma Biopharmaceutical CDMO Product and Solutions
    • 2.16.4 Rentschler Biopharma Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 Rentschler Biopharma Recent Developments and Future Plans
  • 2.17 Northway Biotech
    • 2.17.1 Northway Biotech Details
    • 2.17.2 Northway Biotech Major Business
    • 2.17.3 Northway Biotech Biopharmaceutical CDMO Product and Solutions
    • 2.17.4 Northway Biotech Biopharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 Northway Biotech Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Biopharmaceutical CDMO Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Biopharmaceutical CDMO by Company Revenue
    • 3.2.2 Top 3 Biopharmaceutical CDMO Players Market Share in 2022
    • 3.2.3 Top 6 Biopharmaceutical CDMO Players Market Share in 2022
  • 3.3 Biopharmaceutical CDMO Market: Overall Company Footprint Analysis
    • 3.3.1 Biopharmaceutical CDMO Market: Region Footprint
    • 3.3.2 Biopharmaceutical CDMO Market: Company Product Type Footprint
    • 3.3.3 Biopharmaceutical CDMO Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Biopharmaceutical CDMO Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Biopharmaceutical CDMO Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Biopharmaceutical CDMO Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Biopharmaceutical CDMO Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Biopharmaceutical CDMO Consumption Value by Type (2018-2029)
  • 6.2 North America Biopharmaceutical CDMO Consumption Value by Application (2018-2029)
  • 6.3 North America Biopharmaceutical CDMO Market Size by Country
    • 6.3.1 North America Biopharmaceutical CDMO Consumption Value by Country (2018-2029)
    • 6.3.2 United States Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Biopharmaceutical CDMO Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Biopharmaceutical CDMO Consumption Value by Type (2018-2029)
  • 7.2 Europe Biopharmaceutical CDMO Consumption Value by Application (2018-2029)
  • 7.3 Europe Biopharmaceutical CDMO Market Size by Country
    • 7.3.1 Europe Biopharmaceutical CDMO Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 7.3.3 France Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Biopharmaceutical CDMO Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Biopharmaceutical CDMO Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Biopharmaceutical CDMO Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Biopharmaceutical CDMO Market Size by Region
    • 8.3.1 Asia-Pacific Biopharmaceutical CDMO Consumption Value by Region (2018-2029)
    • 8.3.2 China Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 8.3.5 India Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Biopharmaceutical CDMO Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Biopharmaceutical CDMO Consumption Value by Type (2018-2029)
  • 9.2 South America Biopharmaceutical CDMO Consumption Value by Application (2018-2029)
  • 9.3 South America Biopharmaceutical CDMO Market Size by Country
    • 9.3.1 South America Biopharmaceutical CDMO Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Biopharmaceutical CDMO Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Biopharmaceutical CDMO Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Biopharmaceutical CDMO Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Biopharmaceutical CDMO Market Size by Country
    • 10.3.1 Middle East & Africa Biopharmaceutical CDMO Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Biopharmaceutical CDMO Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Biopharmaceutical CDMO Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Biopharmaceutical CDMO Market Drivers
  • 11.2 Biopharmaceutical CDMO Market Restraints
  • 11.3 Biopharmaceutical CDMO Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Biopharmaceutical CDMO Industry Chain
  • 12.2 Biopharmaceutical CDMO Upstream Analysis
  • 12.3 Biopharmaceutical CDMO Midstream Analysis
  • 12.4 Biopharmaceutical CDMO Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Biopharmaceutical CDMO. Industry analysis & Market Report on Biopharmaceutical CDMO is a syndicated market report, published as Global Biopharmaceutical CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Biopharmaceutical CDMO market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,641.32
    		3,961.98
    		5,282.64
    		3,128.52
    		4,692.78
    		6,257.04
    		492,802.80
    		739,204.20
    		985,605.60
    		291,728.40
    		437,592.60
    		583,456.80
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo